Cyteir Therapeutics, Inc.
DelistedCIK 1662244fmd_0TCQ0AWYWVDXMKSNG1HT3QY4YNManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2023, 15 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Research and development | 17 | 31 | 35 |
| Total operating expenses | 21 | 42 | 48 |
| Operating income | (21) | (42) | (48) |
| Other non-operating income (expense) | 0 | 0 | 2 |
| Income before taxes | (21) | (42) | (46) |
| Net income | (21) | (42) | (46) |